NEW YORK, March 26, 2019 (GLOBE NEWSWIRE) -- Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Amarin Corporation plc (NASDAQ: AMRN) from September 24, 2018 through November 9, 2018, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Amarin investors under the federal securities laws.

If you wish to serve as lead plaintiff, you must move the Court no later than April 23, 2019. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation http://zhanginvestorlaw.com/join-action-form/?slug=amarin-corporation-plc&id=1763 or to discuss your rights or interests regarding this class action, please contact Sophie Zhang, Esq. or Spencer Lee toll-free at 800-991-3756 or email info@zhanginvestorlaw.com, slee@zhanginvestorlaw.com for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) the top-line results Amarin touted concerning its REDUCE-IT trial for Vascepa, a drug intended to treat cardiovascular disease, were not as positive as Amarin had represented; (2) the placebo given to patients in the control arm of the REDUCE-IT trial may have increased the rate of cardiovascular events in those patients; and (3) as a result, Amarin’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class has not been certified. You may retain counsel of your choice. You may take no action at this time and be an absent class member. Your ability to obtain a recovery is not dependent upon being a lead plaintiff.

Zhang Investor Law represents investors worldwide. Attorney Advertising. Prior results do not guarantee similar outcomes.

Zhang Investor Law P.C.
99 Wall Street, Suite 232
New York, New York 10005
info@zhanginvestorlaw.com
tel: (800) 991-3756